Abstract
Sixty-two men who presented with previously untreated metastatic carcinoma of the prostate (D0: 10 patients; D1: 29 patients; D2: 23 patients) received oral megestrol acetate (80 mg twice daily) and minidose estrogen (diethylstibestrol 0.1 mg or ethinyl estradiol 0.05 mg once daily) as a means of achieving total androgen ablation (testicular and adrenal). A high incidence of feminizing side effects (70-74%), a higher than expected rate of cardiovascular complications (18%), an unexpected need for cortisone replacement (13%), and failure of patients with Stage D2 disease to obtain results better than those of standard therapy during the first year of observation suggest this regimen offers no advantage over other more conventional therapy.
MeSH terms
-
Adenocarcinoma / blood
-
Adenocarcinoma / drug therapy*
-
Administration, Oral
-
Aged
-
Aged, 80 and over
-
Cardiovascular Diseases / chemically induced
-
Clinical Trials as Topic
-
Diethylstilbestrol / administration & dosage
-
Diethylstilbestrol / adverse effects
-
Diethylstilbestrol / blood
-
Diethylstilbestrol / therapeutic use
-
Drug Combinations
-
Estradiol Congeners / administration & dosage
-
Estradiol Congeners / adverse effects*
-
Estradiol Congeners / blood
-
Estradiol Congeners / therapeutic use
-
Ethinyl Estradiol / administration & dosage
-
Ethinyl Estradiol / adverse effects
-
Ethinyl Estradiol / blood
-
Ethinyl Estradiol / therapeutic use
-
Follow-Up Studies
-
Humans
-
Lymphatic Metastasis
-
Male
-
Megestrol / administration & dosage
-
Megestrol / adverse effects
-
Megestrol / analogs & derivatives*
-
Megestrol / blood
-
Megestrol / therapeutic use
-
Megestrol Acetate
-
Middle Aged
-
Orchiectomy*
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / drug therapy*
-
Time Factors
Substances
-
Drug Combinations
-
Estradiol Congeners
-
Ethinyl Estradiol
-
Diethylstilbestrol
-
Megestrol
-
Megestrol Acetate